Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people lose roughly 0.5–1kg per week on Wegovy during the active phase of treatment, though weekly variation is wide and no two patterns are identical. That figure comes from the STEP 1 trial, published in the New England Journal of Medicine, which found an average total reduction of around 15% of body weight over 68 weeks at the 2.4mg maintenance dose. Week-to-week, the number on the scale can be smaller, larger, or briefly flat — which is completely normal. Wegovy (semaglutide) is a prescription-only medicine; a prescriber assesses whether it is suitable for you before any treatment begins, and the pace of loss is something you'd discuss with your clinical team rather than target in isolation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The early weeks of semaglutide treatment are titration weeks. Your dose starts at 0.25mg, a level designed to help your body adjust rather than to produce rapid weight loss. Prescribers increase the dose roughly every four weeks until you reach the 2.4mg maintenance dose, and meaningful weekly loss typically builds across that period. So if your first two months feel slow, they usually are, intentionally.
Once established on the maintenance dose, the STEP 1 trial data suggest an average pace of around 0.5–1kg per week during the most active phase, tapering as the body settles at a new weight. Some participants in that trial lost considerably more; others less. Factors like starting weight, physical activity, dietary changes and individual biology all play a role. The total weight loss on Wegovy across a full course reflects this variation, a single weekly figure tells only part of the story.
One thing the trial also makes clear: the bulk of loss happens in the first 52 weeks. Progress after that tends to slow, which is clinically normal and not a sign that treatment has stopped working. If you want to understand what a healthy weekly rate looks like for you specifically, that conversation belongs with your prescriber, not a target you set from a headline number.
Private Wegovy pricing in the UK is set per pen, with each pen covering four weekly doses. Eli Lilly's September 2025 list-price increase for tirzepatide prompted broader market repricing discussion; semaglutide list prices have their own trajectory. Across providers, typical private prices run roughly £150–£375 per month depending on dose and supplier, as widely reported. Those figures are useful context, but headline prices can be misleading.
What a headline price often omits: the consultation fee (charged separately by many services), a prescription fee, delivery charges, and any ongoing clinical review costs. A £149 price point that excludes all of those is a different proposition from one that includes them. How Wegovy is priced in the UK explains the market context in more detail, it's worth reading before comparing providers.
At nume, one transparent price covers the consultation, the prescription, the medicine, next-working-day DPD delivery and seven-day aftercare. We're not the cheapest option available, and that's a deliberate position. The savings on a cheaper listing tend to come from somewhere, shorter consultations, no clinical re-review before repeats, or no aftercare team when you have a question on a Sunday morning. For a prescription medicine, that trade-off matters more than it might for a supplement.
Wegovy is a Prescription-Only Medicine. The MHRA has warned repeatedly about counterfeit pens sold online, including fake semaglutide products seized in large quantities across 2024 and 2025. Some contained insulin; people were hospitalised. The MHRA's Yellow Card scheme allows anyone to report a suspect seller, and checking that any pharmacy you use is listed on the GPhC register takes about thirty seconds.
Discount codes for weight-loss injections from unverified sellers are a red flag, not a saving. Legitimate pharmacies dispensing prescription medicines do not need to use promotional codes to attract patients. At nume, we run no vouchers or discount schemes. What we offer instead is a clinical review you can trace: every prescription is personally approved by a named GPhC-registered prescriber, and your consultation is reviewed again before every repeat.
If you're trying to work out whether Wegovy represents value over the course of treatment, the weekly loss data is one input. The clinical oversight, genuine supply chain and prescriber access are others. A small price difference means very little if the medicine isn't authentic or the dosing guidance is wrong. How much weight semaglutide produces week to week is a reasonable question; whether you're getting real semaglutide in a clinically supervised setting is a more important one.
You can explore our full range of weight-loss treatments and start a free consultation at any point. If you'd like to understand more about the service before doing that, about us covers how nume is built and who reviews prescriptions, and our Wegovy overview walks through eligibility and the treatment process in full.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.